Insulet long-term story keeps getting better, says Canaccord

Canaccord analyst Kyle Rose said Insulet reported solid Q4 results, but guidance came in below Street expectations. The analyst said he expected that to happen and modeled for it, but he sees a compelling new product cycle in Dash. Rose, who sees the company in the early stages of a transformative 24-month period that will see meaningful global share gains, reiterated his Buy rating and $100 price target on Insulet shares.
https://thefly.com/landingPageNews.php?id=2870197